Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Immunotherapy Combinations in Multiple Myeloma - Known Unknowns.

Gormley NJ, Pazdur R.

N Engl J Med. 2018 Nov 8;379(19):1791-1795. doi: 10.1056/NEJMp1803602. No abstract available.

PMID:
30403935
2.

FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.

Bhatnagar V, Gormley NJ, Luo L, Shen YL, Sridhara R, Subramaniam S, Shen G, Ma L, Shord S, Goldberg KB, Farrell AT, McKee AE, Pazdur R.

Oncologist. 2017 Nov;22(11):1347-1353. doi: 10.1634/theoncologist.2017-0229. Epub 2017 Sep 13.

3.

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.

Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M, Davies FE, Di Bacco A, Dickey JS, Gutman SI, Higley HR, Hussein MA, Jessup JM, Kirsch IR, Little RF, Loberg RD, Lohr JG, Mukundan L, Omel JL, Pugh TJ, Reaman GH, Robbins MD, Sasser AK, Valente N, Zamagni E.

Clin Cancer Res. 2017 Aug 1;23(15):3980-3993. doi: 10.1158/1078-0432.CCR-16-2895. Epub 2017 Apr 20.

4.

Measurable residual disease testing in acute myeloid leukaemia.

Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB.

Leukemia. 2017 Jul;31(7):1482-1490. doi: 10.1038/leu.2017.113. Epub 2017 Apr 7. Review.

PMID:
28386105
5.

FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma.

Gormley NJ, Ko CW, Deisseroth A, Nie L, Kaminskas E, Kormanik N, Goldberg KB, Farrell AT, Pazdur R.

Clin Cancer Res. 2017 Nov 15;23(22):6759-6763. doi: 10.1158/1078-0432.CCR-16-2870. Epub 2017 Mar 1.

6.

Minimal Residual Disease as a Potential Surrogate End Point-Lingering Questions.

Gormley NJ, Farrell AT, Pazdur R.

JAMA Oncol. 2017 Jan 1;3(1):18-20. doi: 10.1001/jamaoncol.2016.3112. No abstract available.

PMID:
27632052
7.

Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.

Gormley NJ, Turley DM, Dickey JS, Farrell AT, Reaman GH, Stafford E, Carrington L, Marti GE.

Cytometry B Clin Cytom. 2016 Jan;90(1):73-80. doi: 10.1002/cyto.b.21268. Epub 2015 Jul 25.

8.

Recombinant human factor VIIa for alveolar hemorrhage following allogeneic stem cell transplantation.

Elinoff JM, Bagci U, Moriyama B, Dreiling JL, Foster B, Gormley NJ, Salit RB, Cai R, Sun J, Beri A, Reda DJ, Fakhrejahani F, Battiwalla M, Baird K, Cuellar-Rodriguez JM, Kang EM, Pavletic SZ, Fowler DH, John Barrett A, Lozier JN, Kleiner DE Jr, Mollura DJ, Childs RW, Suffredini AF.

Biol Blood Marrow Transplant. 2014 Jul;20(7):969-78. doi: 10.1016/j.bbmt.2014.03.015. Epub 2014 Mar 20.

9.

The rising incidence of intentional ingestion of ethanol-containing hand sanitizers.

Gormley NJ, Bronstein AC, Rasimas JJ, Pao M, Wratney AT, Sun J, Austin HA, Suffredini AF.

Crit Care Med. 2012 Jan;40(1):290-4. doi: 10.1097/CCM.0b013e31822f09c0. Review.

Supplemental Content

Loading ...
Support Center